No connection

Search Results

BEAM vs LEGN

BEAM
Beam Therapeutics Inc.
BEARISH
Price
$31.56
Market Cap
$3.2B
Sector
Healthcare
AI Confidence
65%
LEGN
Legend Biotech Corporation
BEARISH
Price
$18.16
Market Cap
$3.36B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
BEAM
--
LEGN
--
Forward P/E
BEAM
-6.85
LEGN
15.79
P/B Ratio
BEAM
3.22
LEGN
3.35
P/S Ratio
BEAM
57.5
LEGN
3.26
EV/EBITDA
BEAM
-4.93
LEGN
-48.64

Profitability

Gross Margin
BEAM
0.0%
LEGN
20.03%
Operating Margin
BEAM
-1307.6%
LEGN
-6.72%
Profit Margin
BEAM
0.0%
LEGN
-28.85%
ROE
BEAM
-47.19%
LEGN
-29.06%
ROA
BEAM
-23.48%
LEGN
-5.01%

Growth

Revenue Growth
BEAM
-32.0%
LEGN
64.2%
Earnings Growth
BEAM
--
LEGN
--

Financial Health

Debt/Equity
BEAM
0.16
LEGN
0.41
Current Ratio
BEAM
6.02
LEGN
1.96
Quick Ratio
BEAM
5.89
LEGN
1.88

Dividends

Dividend Yield
BEAM
--
LEGN
--
Payout Ratio
BEAM
0.0%
LEGN
0.0%

AI Verdict

BEAM BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 1/9, indicating severe operational and profitability concerns. Despite a strong analyst recommendation of 'strong_buy' and a target price implying 44% upside, the company exhibits negative gross and operating margins, deteriorating revenue growth, and deeply negative returns on equity and assets. Insider selling activity totaling $3.19M over the past six months contradicts the bullish analyst sentiment, while valuation multiples like a Price/Sales ratio of 57.50 are extremely stretched relative to fundamentals. Although the current ratio is strong at 6.02, suggesting near-term liquidity safety, the lack of Altman Z-Score and persistent unprofitability elevate long-term sustainability risks.

Strengths
Exceptionally strong liquidity position with a current ratio of 6.02 and quick ratio of 5.89, providing runway for R&D and operations
Low debt burden with a Debt/Equity ratio of 0.16, well below sector average of 2.71, reducing financial risk
Analyst consensus is strongly bullish with a 'strong_buy' rating from 15 analysts and a mean target price of $45.47
Risks
Critically low Piotroski F-Score of 1/9 signals severe financial distress and poor fundamental strength
Operating margin of -1307.60% and gross margin of 0.00% indicate no viable path to profitability in the near term
Revenue growth is sharply negative at -32.00% YoY, reversing prior growth trends and signaling weakening commercial momentum
LEGN BEARISH

LEGN exhibits severe financial instability as evidenced by a critical Piotroski F-Score of 1/9, indicating poor operational health. While the company shows impressive top-line revenue growth of 64.20%, this is offset by consistent earnings misses (average surprise of -66.26% over the last 4 quarters) and a devastating technical trend (0/100). There is a stark disconnect between the bullish analyst target of $57.22 and the actual price performance, which has declined over 41% in the last year. The stock currently behaves as a high-risk speculative asset with failing fundamental health markers.

Strengths
Strong YoY revenue growth of 64.20%
Low Debt/Equity ratio of 0.41
Healthy liquidity with a Current Ratio of 1.96
Risks
Critical Piotroski F-Score (1/9) indicating fundamental weakness
Severe technical breakdown with 0/100 trend score
Consistent failure to meet earnings estimates (1/4 beats in last 4 quarters)

Compare Another Pair

BEAM vs LEGN: Head-to-Head Comparison

This page compares Beam Therapeutics Inc. (BEAM) and Legend Biotech Corporation (LEGN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile